The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results
Yıl: 2021 Cilt: 30 Sayı: 1 Sayfa Aralığı: 1 - 7 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2020.63634 İndeks Tarihi: 18-05-2021
The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results
Öz: Objectives: The aim of the study was to investigate the role of 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for evaluating the efficacy of radiofrequency ablation (RFA) in primary and metastatic liver tumors compared with contrast-enhanced ultrasound examination (CEUS) and to find its place in overall staging and the follow-up diagnostic algorithm.Methods: PET/CT examinations were performed 2 months after RFA for 20 patients with a total of 34 liver lesions. CEUS was performed within 10 days after PET/CT, and the results were compared. Seven patients were staged with PET/CT and the others with a contrast-enhanced CT.Results: A total of 48 18F-FDG PET/CT examinations were performed. We observed complete response in 8 patients (40%), 2 patients (10%) had stable disease, one (5%) had partial response, and 9 patients (45%) had progression (including 2 cases with extrahepatic involvement). Compared with CEUS, there was a mismatch in 3 cases. Five patients underwent additional RFA for 7 lesions.Conclusion: According to our preliminary data, PET/CT may be a valuable method, with comparable or eventually even better sensitivity than CEUS, for early evaluation of the efficacy of RFA for the treatment of metastatic and primary liver lesions and planning of future treatment. PET/CT might be recommended as a staging method before undergoing RFA of liver lesions for determining the local extent of the disease in the liver in combination with CEUS with an advantage in visualization of extrahepatic involvement. However, more patients need to be investigated in order to demonstrate and confirm the obtained results with certainty.
Anahtar Kelime: Metastatik ve Primer Karaciğer Tümörlerinde Radyofrekans Ablasyonun Etkinliğinin Değerlendirilmesinde 18F-FDG PET/BT’nin Rolü: Ön Sonuçlar
Öz: Amaç: Bu çalışmanın amacı, primer ve metastatik karaciğer tümörlerinde radyofrekans ablasyonunun (RFA) etkinliğini değerlendirmede 18flor-florodeoksiglukoz (18F-FDG) pozitron emisyon tomografisi/bilgisayarlı tomografinin (PET/BT) rolünü kontrastlı ultrason tetkikine (CEUS) kıyasla araştırmak ve genel evreleme ve takip tanı algoritmasındaki yerini bulmaktır.Yöntem: Toplam 34 karaciğer lezyonu olan 20 hastaya RFA’dan 2 ay sonra PET/BT tetkikleri yapıldı. PET/BT’den sonraki 10 gün içinde CEUS yapıldı ve sonuçlar karşılaştırıldı. Yedi hasta PET/BT ile diğerleri ise kontrastlı BT ile evrelendirildi.Bulgular: Toplam 48 adet 18F-FDG PET/BT incelemesi yapıldı. Sekiz hastada (%40) tam yanıt, 2 hastada (%10) stabil hastalık, 1 hastada (%5) kısmi yanıt ve 9 hastada (%45) progresyon (ekstrahepatik tutulumlu 2 olgu dahil) gözlemlendi. CEUS ile karşılaştırıldığında, 3 olguda uyumsuzluk bulundu. Beş hastaya, toplam 7 lezyon için ek RFA uygulandı.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Cornelis F, Sotirchos V, Violari E, Sofocleous CT, Schoder H, Durack JC, Siegelbaum RH, Maybody M, Humm J, Solomon SB. 18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation. J Nucl Med 2016;57:1052-1057.
- 2. Takahashi H, Berber E. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobiliary Surg Nutr 2020;9:49-58.
- 3. O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016;280:576-584.
- 4. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 2007;10:38-46.
- 5. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:825-827.
- 6. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med 2013;34:11-29.
- 7. Larsen LP. Role of contrast enhanced ultrasonography in the assessment of hepatic metastases: A review. World J Hepatol 2010;2:8-15.
- 8. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-197.
- 9. McLoney ED, Isaacson AJ, Keating P. The Role of PET Imaging Before, During, and After Percutaneous Hepatic and Pulmonary Tumor Ablation. Semin Intervent Radiol 2014;31:187-192.
- 10. Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 2005;46:520-525.
- 11. Travaini LL, Trifirò G, Ravasi L, Monfardini L, Della Vigna P, Bonomo G, Chiappa A, Mallia A, Ferrari M, Orsi F, Paganelli G. Role of [18F] FDG-PET/ CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 2008;35:1316-1322.
- 12. Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDGPET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med 2013;27:58-64.
- 13. Samim M, Prevoo W, de Wit-van der Veen BJ, Kuhlmann KF, Ruers T, van Hillegersberg R, van den Bosch MAAJ, Verkooijen HM, Lam MGEH, Stokkel MPM. 18F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases. Eur J Nucl Med Mol Imaging 2017;44:1165-1175.
- 14. Poulou LS, Ziakas PD, Ziogas DC, Doxani C, Xyla V, Vakrinos G, Voulgarelis M, Thanos L. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis. Biomarkers 012;17:532-538.
| APA | Mateva G, DİMİTROVA KOSTADİNOVA I, HANDZHİEV S (2021). The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. , 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| Chicago | Mateva Gabriela,DİMİTROVA KOSTADİNOVA Irena,HANDZHİEV Stoyan The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. (2021): 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| MLA | Mateva Gabriela,DİMİTROVA KOSTADİNOVA Irena,HANDZHİEV Stoyan The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. , 2021, ss.1 - 7. 10.4274/mirt.galenos.2020.63634 |
| AMA | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. . 2021; 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| Vancouver | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. . 2021; 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| IEEE | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S "The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results." , ss.1 - 7, 2021. 10.4274/mirt.galenos.2020.63634 |
| ISNAD | Mateva, Gabriela vd. "The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results". (2021), 1-7. https://doi.org/10.4274/mirt.galenos.2020.63634 |
| APA | Mateva G, DİMİTROVA KOSTADİNOVA I, HANDZHİEV S (2021). The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. Molecular Imaging and Radionuclide Therapy, 30(1), 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| Chicago | Mateva Gabriela,DİMİTROVA KOSTADİNOVA Irena,HANDZHİEV Stoyan The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. Molecular Imaging and Radionuclide Therapy 30, no.1 (2021): 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| MLA | Mateva Gabriela,DİMİTROVA KOSTADİNOVA Irena,HANDZHİEV Stoyan The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. Molecular Imaging and Radionuclide Therapy, vol.30, no.1, 2021, ss.1 - 7. 10.4274/mirt.galenos.2020.63634 |
| AMA | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. Molecular Imaging and Radionuclide Therapy. 2021; 30(1): 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| Vancouver | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results. Molecular Imaging and Radionuclide Therapy. 2021; 30(1): 1 - 7. 10.4274/mirt.galenos.2020.63634 |
| IEEE | Mateva G,DİMİTROVA KOSTADİNOVA I,HANDZHİEV S "The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results." Molecular Imaging and Radionuclide Therapy, 30, ss.1 - 7, 2021. 10.4274/mirt.galenos.2020.63634 |
| ISNAD | Mateva, Gabriela vd. "The Role of 18F-FDG PET/CT in Evaluating the Efficacy of Radiofrequency Ablation in Metastatic and Primary Liver Tumors: Preliminary Results". Molecular Imaging and Radionuclide Therapy 30/1 (2021), 1-7. https://doi.org/10.4274/mirt.galenos.2020.63634 |
